Stock Taper
SCREENER COMPARE ANY 2 STOCKS
JBIO
JADE BIOSCIENCES, INC.
NASDAQ
$20.84
▼ DOWN 2.11% (-0.45)

KEY STATISTICS

Market Cap$1.27 B
52w High$28.00
52w Low$6.91
Dividend Yield23.67%
FrequencyIrregular
P/E-10.32
Volume357.92K
Shares Out.60.86M

COMPANY

LEADERSHIP

Tom Frohlich
CHIEF EXECUTIVE
Tom Frohlich

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 30, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
55

PRICE TARGET

Target High$55.00
Target Low$40.00
Target Median$47.00
Target Consensus$46.71

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2025-04-29Reverse1:35

PRICE

$20.84 ▼ DOWN 2.11% (−$0.45)
OVERLAYS
$20.80$21.00$21.20$21.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM20.84

About Jade Biosciences, Inc.

https://jadebiosciences.com ↗

Jade Biosciences, Inc. is a biotech firm developing therapies for autoimmune diseases, with lead asset JADE-001 targeting the APRIL pathway for IgA nephropathy, entering clinical trials in late 2025.

INDUSTRY

Biotechnology

A PRODUCT JADE BIOSCIENCES, INC. IS KNOWN FOR

JADE101
JADE101

Jade Biosciences' lead investigational anti-APRIL monoclonal antibody targets IgA nephropathy, a chronic kidney disease, reflecting the company's focus on developing novel autoimmune disease therapies.

COMPETITORS

COMPETITOR
NVS COMPARE
TVTX COMPARE
VERA COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
88
LISTED HERE
15
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.7M
XBI
0.29% · 1.6M
IWM
0.02% · 841.0K
FFSM
0.15% · 89.7K
PSC
0.06% · 79.5K
LABU
0.20% · 59.4K
XRS2.F
0.02% · 29.8K
BBC
0.83% · 20.4K
RSSL
0.02% · 15.5K
GSSC
0.02% · 12.5K
URTY
0.01% · 1.3K
AVSC
0.00% · 1.2K
SZNE
0.06% · 712
RESM
0.03% · 95
SC0K.DE
0.02% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.68%
HOLDERS
175
TOP 12 OF 175 · RANKED BY POSITION SIZE
Fmr LLC
9.1M sh · $202.8M
Fairmount Funds Management LLC
4.6M sh · $63.98M
Ra Capital Management, L.P.
3.7M sh · $51.58M
Bellevue Group AG
3.5M sh · $49.2M
Vr Adviser, LLC
3.2M sh · $49.69M
Janus Henderson Group Plc
3.1M sh · $43.56M
Blackrock, Inc.
2.9M sh · $44.29M
Paradigm Biocapital Advisors LP
2.9M sh · $63.49M
Franklin Resources Inc
2.8M sh · $62.04M
State Street Corp
2.3M sh · $51.89M
Deep Track Capital, LP
2.3M sh · $19.68M
Vanguard Group Inc
2.1M sh · $32.34M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Eisner Mark
Purchase · 47.7K shares
2026-06-25
★
Eisner Mark
— · —
2026-06-25
★
DIRECTOR
CAIN CHRISTOPHER W.
Purchase · 34.8K shares
2026-06-09
★
DIRECTOR
DOBMEIER ERIC
Purchase · 34.8K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM BTIG BUY HC Wainwright & Co. BUY Guggenheim BUY

SECTORS PEERS

PEERPRICE
TECX$35.62COMPARE
CTNM$17.05COMPARE
SLN$13.42COMPARE
KYTX$8.37COMPARE
LYEL$14.53COMPARE
ACIU$2.65COMPARE
GNLX$2.66COMPARE
ALDX$1.49COMPARE